PH30757A - Insulin formulation. - Google Patents

Insulin formulation.

Info

Publication number
PH30757A
PH30757A PH48764A PH48764A PH30757A PH 30757 A PH30757 A PH 30757A PH 48764 A PH48764 A PH 48764A PH 48764 A PH48764 A PH 48764A PH 30757 A PH30757 A PH 30757A
Authority
PH
Philippines
Prior art keywords
insulin
formulation
zinc
total
present
Prior art date
Application number
PH48764A
Other languages
English (en)
Inventor
Hoffmann James Arthur
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH30757A publication Critical patent/PH30757A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH48764A 1993-08-13 1994-08-09 Insulin formulation. PH30757A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/106,106 US5534488A (en) 1993-08-13 1993-08-13 Insulin formulation

Publications (1)

Publication Number Publication Date
PH30757A true PH30757A (en) 1997-10-17

Family

ID=22309529

Family Applications (1)

Application Number Title Priority Date Filing Date
PH48764A PH30757A (en) 1993-08-13 1994-08-09 Insulin formulation.

Country Status (27)

Country Link
US (1) US5534488A (pl)
EP (1) EP0646379B1 (pl)
JP (1) JPH07149660A (pl)
KR (1) KR950005324A (pl)
CN (1) CN1109364A (pl)
AT (1) ATE207761T1 (pl)
AU (1) AU674975B2 (pl)
BR (1) BR9403204A (pl)
CA (1) CA2129763A1 (pl)
CO (1) CO4230235A1 (pl)
CZ (1) CZ193794A3 (pl)
DE (1) DE69428860T2 (pl)
DK (1) DK0646379T3 (pl)
ES (1) ES2164691T3 (pl)
HU (1) HUT67853A (pl)
IL (1) IL110581A0 (pl)
NO (1) NO942959L (pl)
NZ (1) NZ264197A (pl)
PE (1) PE14495A1 (pl)
PH (1) PH30757A (pl)
PL (1) PL177002B1 (pl)
PT (1) PT646379E (pl)
RU (1) RU2135205C1 (pl)
TW (1) TW326394B (pl)
UA (1) UA27874C2 (pl)
YU (1) YU50494A (pl)
ZA (1) ZA945939B (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578238A (en) * 1992-10-30 1996-11-26 Lord Corporation Magnetorheological materials utilizing surface-modified particles
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
EP1396272A1 (en) * 1997-12-23 2004-03-10 Eli Lilly & Company Insoluble Insulin Compositions for Controlling Blood Glucose
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
WO2001000675A1 (en) * 1999-06-29 2001-01-04 Eli Lilly And Company Protamine-free insoluble acylated insulin compositions
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
ATE328605T1 (de) * 2000-03-24 2006-06-15 Genentech Inc Verwendung von insulin zur behandlung von knorpelkrankheiten
WO2003057650A2 (en) 2002-01-09 2003-07-17 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
US6743371B2 (en) 2000-10-06 2004-06-01 The Adviser-Defence Research & Development Organisation Ministry Of Defence, Government Of India Magneto sensitive fluid composition and a process for preparation thereof
EP1344229B1 (en) * 2000-11-29 2008-03-05 The Adviser Defence Research & Development Organisation, Ministry of Defence, Government of India A magnetorheological fluid composition and a process for preparation thereof
PL374181A1 (pl) * 2001-02-09 2005-10-03 Genentech, Inc. Krystalizacja IGF-1
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
EP1711220A1 (en) * 2004-01-16 2006-10-18 Biodel, Inc. Sublingual drug delivery device
WO2005089722A1 (en) * 2004-03-12 2005-09-29 Biodel, Inc. Rapid acting drug delivery compositions
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
CA2897225C (en) 2004-05-06 2017-12-05 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
CA2566161C (en) * 2004-05-14 2013-10-01 Emisphere Technologies, Inc. Aryl ketone compounds and compositions for delivering active agents
US7605123B2 (en) 2004-07-19 2009-10-20 Biocon Ltd. Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof
US20100048454A1 (en) * 2004-08-03 2010-02-25 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
US20060078622A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
CA2649109A1 (en) * 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
PL2134351T3 (pl) 2007-03-13 2017-10-31 Jds Therapeutics Llc Sposoby i kompozycje do przedłużonego uwalniania chromu
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
JP5868594B2 (ja) 2007-10-16 2016-02-24 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ 経口投与可能な固形医薬組成物及びそのプロセス
US20090175840A1 (en) * 2008-01-04 2009-07-09 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
PT2498801T (pt) 2009-11-13 2018-05-02 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendin-4(1-39)-lys6-nh2 e metionina
RU2537239C2 (ru) 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
MX2012009618A (es) * 2010-02-22 2013-02-26 Univ Case Western Reserve Preperaciones de analogo de insulina de larga accion en formas solubles y cristalinas.
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
AU2012223282B2 (en) 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
HUE062573T2 (hu) 2014-12-12 2023-11-28 Sanofi Aventis Deutschland Glargin inzulin/lixiszenatid rögzített arányú készítmény
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB2564295A (en) 2016-02-11 2019-01-09 Nutrition 21 Llc Chromium containing compositions for improving health and fitness

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
US2882202A (en) * 1950-04-05 1959-04-14 Novo Terapeutisk Labor As Insulin crystal preparations and methods of producing them
US2882203A (en) * 1951-06-26 1959-04-14 Novo Terapeutisk Labor As Injectable insulin preparation with protracted effect
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US2819999A (en) * 1953-11-13 1958-01-14 Novo Terapeutisk Labor As Process for crystallization of insulin using freeze dried insulin as seeding material
US2799622A (en) * 1953-11-14 1957-07-16 Novo Terapeutisk Labor As Process of producing insulin crystals of substantially uniform size and compositions thereof
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus

Also Published As

Publication number Publication date
US5534488A (en) 1996-07-09
ATE207761T1 (de) 2001-11-15
KR950005324A (ko) 1995-03-20
CA2129763A1 (en) 1995-02-14
JPH07149660A (ja) 1995-06-13
CO4230235A1 (es) 1995-10-19
NZ264197A (en) 1997-01-29
RU2135205C1 (ru) 1999-08-27
AU7024794A (en) 1995-02-23
EP0646379B1 (en) 2001-10-31
PT646379E (pt) 2002-03-28
IL110581A0 (en) 1994-11-11
ZA945939B (en) 1996-02-08
UA27874C2 (uk) 2000-10-16
TW326394B (en) 1998-02-11
BR9403204A (pt) 1995-04-18
NO942959D0 (no) 1994-08-09
HUT67853A (en) 1995-05-29
DE69428860T2 (de) 2002-05-02
ES2164691T3 (es) 2002-03-01
PE14495A1 (es) 1995-06-02
CN1109364A (zh) 1995-10-04
DE69428860D1 (de) 2001-12-06
HU9402287D0 (en) 1994-09-28
PL304600A1 (en) 1995-02-20
AU674975B2 (en) 1997-01-16
DK0646379T3 (da) 2001-12-03
NO942959L (no) 1995-02-14
YU50494A (sh) 1997-01-08
CZ193794A3 (en) 1995-03-15
PL177002B1 (pl) 1999-09-30
EP0646379A1 (en) 1995-04-05

Similar Documents

Publication Publication Date Title
IL110581A0 (en) Insulin formulation
AU610636B2 (en) Stabilised human protein preparations
IL72494A (en) Homologues of aprotinin with other aminoacids in position 15,instead of lysine,their preparation and pharmaceutical compositions containing them
WO1995013297A3 (en) Improved immunogenic compositions against human gastrin 17
DK168790D0 (pl)
CA2015186A1 (en) Nutrient composition
NZ228710A (en) Modified "echistatin" and anti-clotting pharmaceutical composition
AU2670495A (en) Ifn-beta liquid formulations
AU8188087A (en) Variants of hirudin, their use and their preparation
AU1926188A (en) N-benzoyl-n'-2,5-dihalo-4-perfluoroalkoxyphenylureas, their preparation and use in the control of pests
AU6406590A (en) Porcine lactoferrin amino acid and cdna sequence
AU4225385A (en) After-treating nylon or natural polyamides
AU8375891A (en) Antioxidant system based on a basic amino acid in combination with a tocopherol or derivative thereof and a nonthiolated polypeptide, and compositions containing the same
HU9402648D0 (en) 3,4-dioxo-1-cyclobuten-1-yl-substituted (indolyl-alkyl)-pyridine- and -pyrimidine derivatives and antimigraine composition containing them as active componens
MD1714G2 (ro) Compoziţie terapeutică în formă de sirop, conţinând N-acetilcisteină
EP0300741A3 (en) Human thymopoietin
CA2153071A1 (en) Derivatized calcitonins
EP0292302A3 (en) Human splenin
HU201445B (en) Herbicide composition containing sulfonyl-urea derivative as active component and glycinamide derivative as antidotum
TH17521A (th) สูตรผสมอินซูลิน
AU6985287A (en) 1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo)-3- {(substituted amino)carbonyl}-2-thioxo(or oxo)-5-pyrimidine -carboxylic acids and esters
TH17521EX (th) สูตรผสมอินซูลิน